Viridian Therapeutics, Inc. (VRDN): This Small-Cap Stock Is Ready To Explode [Yahoo! Finance]
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at HC Wainwright from $27.00 to $34.00. They now have a "buy" rating on the stock.
Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data